On January 6, 2023, the FDA granted lecanemab-irmb (Leqembi) accelerated approval for treating mild cognitive impairment and mild dementia in patients with Alzheimer disease.
Kevin Chamberlain, PharmD, FASCP
Advertisement
Articles by Kevin Chamberlain, PharmD, FASCP
Overall median survival was higher in participants taking quizartinib, according to results from QuANTUM-First trial.
Mavacamten improves functional capacity and symptoms in adults with New York Heart Association class II-III obstructive HCM.
Advertisement
Latest Updated Articles
First-in-Class Treatment for Obstructive Hypertrophic Cardiomyopathy Is Approved by FDAPublished: October 11th 2022 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
Pharmacists Shifting from Reactive to Proactive Diabetes Counselors
2
Investigators Evaluate Decline in Percentage of Patients With COPD Using Inhaled Corticosteroids
3
Naloxone Sales Highlight Limited OTC Use, Access Challenges
4
Is it Safe for Birth Control Users to Go Years Without a Period?
5
